Customizing the therapeutic response of signaling networks to promote antitumor responses by drug combinations.
about
NRF2 Regulates HER2 and HER3 Signaling Pathway to Modulate Sensitivity to Targeted Immunotherapies.Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth.A novel mechanism of action of HER2 targeted immunotherapy is explained by inhibition of NRF2 function in ovarian cancer cells.Adaptive stress signaling in targeted cancer therapy resistance.Informatics Approaches for Predicting, Understanding, and Testing Cancer Drug Combinations.Drug-diagnostics co-development in oncology.Systems analysis of drug-induced receptor tyrosine kinase reprogramming following targeted mono- and combination anti-cancer therapy.
P2860
Q36387554-578CDBAD-F68D-4C50-BD77-00116A23316DQ36592140-1E36A3BE-488F-4CA5-A525-47543DD8B50CQ37689036-48E94F92-3B9B-4C40-BAFF-A0DC471EF65DQ38363739-7684B243-3234-4C75-BAC7-289C27D9934EQ38668684-CCE75A77-9E4C-4657-B782-7EDEC0A4AF8BQ41883789-A7C837C0-4AAE-4365-BE03-94DC6A8D514AQ42109090-14296EB6-DD2F-4BAD-B4D6-0E50B618520E
P2860
Customizing the therapeutic response of signaling networks to promote antitumor responses by drug combinations.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Customizing the therapeutic re ...... esponses by drug combinations.
@en
type
label
Customizing the therapeutic re ...... esponses by drug combinations.
@en
prefLabel
Customizing the therapeutic re ...... esponses by drug combinations.
@en
P2093
P2860
P356
P1476
Customizing the therapeutic re ...... responses by drug combinations
@en
P2093
Alexey Goltsov
Gregory Goltsov
James Bown
Simon P Langdon
P2860
P356
10.3389/FONC.2014.00013
P577
2014-02-05T00:00:00Z